The Massachusetts Biotechnology Council (MassBio) just released Impact 2020, a report on the state of the biotechnology and life sciences cluster in Massachusetts.
The extensive report issues a call to action for Massachusetts stakeholders-across industry, academia, healthcare networks, payers and government-to take steps to safeguard the Commonwealth’s definitive, but fragile, leadership position in life sciences and innovation.
MassBio’s strategic reports have been key to strengthening the regional life sciences cluster, which today is recognized as the global leader for life sciences innovation.
Impact 2020 examines the balance between value-based, evidence-based medicine in the era of healthcare reform and the uncertainty it creates for investors and entrepreneurs who seek reward for innovation and risk-taking.
The report also analyzes new challenges in capital formation to fund new companies and drive forward new potential medicines, diagnostics and devices. As the cost and risk of bringing new products to market has increased, traditional investors have evolved models that spread that risk. New players, including disease foundations, wealthy individuals, and even crowdsourcing organizations are filling a void left by a decrease in traditional sources of capital.